Navigating an executive leadership change? Use our eBook to facilitate a smooth transition.Download Now

Westicke Partners

Close

Kymera Therapeutics, Inc.

$200 Million Initial Public Offering

Case Study: Kymera Therapeutics, Inc.

Westwicke began working with biopharmaceutical company Kymera Therapeutics in April 2020, providing strategic advice for the company’s IPO, throughout the underwriter selection process, S-1 drafting process, and four-day virtual roadshow. In August 2020, Kymera priced its upsized IPO at $20 per share.

Download the case study to learn how Westwicke’s strategic advice led to a successful IPO, with shares closing up 66.3%.

Have News to Release?

Find out whether you should file a Form 8-K, issue a press release, or do both by using our easy-to-reference chart, Form 8K vs. Press Release: What’s the Difference?

Our Locations